February 1, 2011 |
07.00-08.45 hr |
Registration |
09.00 hr
|
|
Inauguration ceremony
Keynote Address
A Nobel Prize by Chance!
Prof. (Dr.) Rolf Zinkernagel
Nobel Laureate ( Medicine )
Zurich, Switzerland |
11.00 hr |
Tea/Coffee Break |
Session I
Chairperson
Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche
Dr. Y. K. Gupta
Professor & Head, Dept of Pharmacology, All India Institute of Medical Sciences, Delhi, India
|
12.00 hr |
|
Therapeutic Science and Medicine: New Models for Academic--Industry Interactions
Dr. William W. Chin, MD, PhD
Executive Dean for Research
Professor of Medicine
Harvard Medical School
Retired Senior Vice President, Discovery Research & Clinical Investigation, Eli Lilly, USA |
12.45 hr |
|
State of Oncology Therapeutic Research : A look ahead
Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche |
13.10 hr |
Lunch break / Poster Session |
14.30 hr |
|
Synthetic Lethality in Cancer Treatment: Current status of PARP Inhibitors
Dr. Hilary Calvert, MD
Director of Cancer Drug Discovery and Development,
UCL Cancer Institute, London, UK |
15.15 hr |
|
DNA repair dysfunctionality in lung cancer
Dr. Jean-Charles Soria, MD
Institut Gustave Roussy,
Head of the Early Therapeutics Innovations Service (SITEP), Villejuif, France |
16.00 hr |
Tea/Coffee Break |
16.30 hr |
|
Outliers, Invisible Gorillas, and Fellow Travelers-Understanding the Difference for Molecularly Targeted Drug Development
Dr. Anthony W. Tolcher, MD
Director of START (South Texas Accelerated Research Therapeutics) and Clinical Professor of Medicine in the Division of Medical Oncology, University of Texas Health Science Center, San Antonio, USA |
17.15 hr |
|
PI3 Kinase inhibitor for the treatment of cancer
Dr. Pablo Cagnoni, MD
SVP Global Head, Clinical Development,
Novartis Pharmaceuticals, Switzerland |
18.00 hr |
Panel Discussion |
- Dr. Kapil Dhingra
- Dr. Rolf Zinkernagel
- Dr. William W. Chin
- Dr. Hilary Calvert
- Dr. Jean-Charles Soria
- Dr. Anthony W. Tolcher
- Dr. Pablo Cagnoni
|
February 2, 2011 |
Session II
Chairperson Dr. Hilary Calvert, MD
Director of Cancer Drug Discovery and Development,
UCL Cancer Institute, London, UK
Dr. S. D. Seth
Advisor, Indian Council of Medical Research |
09.00 hr |
|
Harnessing the immune system to treat cancer – A reality at last
Dr. Kapil Dhingra
Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche |
09.45 hr |
|
Manipulating the Inhibitory Arm of the Immune System, a Needed Strategy for Cancer Therapy
Dr. Samir N. Khleif, M.D.
Head, Cancer Vaccine Section, Investigator, National Cancer Institute
Bethesda, USA |
10.30 hr |
|
T cell-engaging BiTE antibodies for cancer therapy
Dr. Patrick Baeuerle, PhD
Chief Scientific Officer,
Micromet |
11.15 hr |
Tea/Coffee Break |
11.45 hr |
|
Oncology Clinical Research : India
Prof. Vinod Raina, MD, FRCP.
Head Dept of Medical Oncology &
Head Delhi Cancer Registry
Institute of Rotary Cancer Hospital
All India Institute of Medical Sciences (AIIMS)
|
12.30 hr |
|
Targeting Multiple Myeloma: Use of Translational Research to Inform a Development Path for the KSP inhibitor ARRY-520
Dr. Duncan Walker, PhD
Senior Director, Translational Medicine, Array Biopharma, USA |
13.15 hr |
Lunch Break / Poster Session |
Session III
Chairperson
Dr. Pankaj Shah
Director, Gujarat Cancer Research Institute
Dr. J. S. Yadav
Director, Indian Institute of Chemical Technology |
15.00 hr |
|
Estrogen receptor beta-selective compounds and their potential role in cancer therapy
Anneli Hallgren
CSO, Karobio
Sweden |
15.45 hr |
|
Cancer Metabolism: The Warburg Effect Revisited
Dr. Rajesh Chopra MD, PhD
Vice President Translational Development, Celgene, USA |
16.30 hr |
Tea/Coffee Break |
17.00 hr |
|
From Fragment to clinic: Translational biomarkers for clinical candidates derived from fragment-based drug design.
Dr. John Lyons, MSc PhD,
VP Translational Research & Development,
Astex Pharma |
17.45 hr |
|
'Innovation management in drug discovery'
Dr. Mikio Arisawa
Retd. Head of Discovery,
Chugai (Roche Group), Japan |
18.30 hr |
Panel discussion |
- Dr. Kapil Dhingra
- Dr. Samir N. Khleif
- Dr. Patrick Beauerle
- Dr. Anneli Hallgren
- Dr. Duncan Walker
- Dr. Rajesh Chopra
- Dr. Mikio Arisawa
- Dr. Vinod Raina
|
19.00 hr |
Workshop by Cambridgesoft Corp.
Informatics solution for Research,
Cambridgesoft Corp, USA |
19.30 hr |
Workshop by Biotron Healthcare
HTRF chemistry and applications in drug discovery
Roderick Haroutunian, CIS BIO, France
BMG omega / PHERAstar: new standard for multi lable detection
John Abbenante, BMG Lab Tech Australia |
20.00 hr |
Workshop by GE Healthcare
Modern Bioanalytics- Getting closer to understanding your product
Mr. Lalith Kishore, GE Healthcare |
February 3, 2011 |
Session IV
Chairperson
Dr. Richard DiMarchi, PhD
Gill Professor of Biochemistry, Indiana University, USA Dr. John Amatruda, MD,
Retired Merck Sr. VP & Franchise Head, Diabetes/Obesity, USA |
09.00 hr |
|
New Therapies for the Treatment of Type II Diabetes: Challenges and Opportunities
Nancy Thornberry
Sr. VP, Metabolic Franchise Head, Merck Research Labs, USA |
09.45 hr |
|
CNS Integration of Systems Metabolism: Target Opportunities for Diabetes Prevention and Therapy
Dr. Matthias Tschoep, MD
Professor of Endocrinology, University of Cincinnati, USA |
10.30 hr |
Tea/Coffee Break |
11.00 hr |
|
MicroRNAs: Function in metabolism and therapeutic opportunities
Dr. Markus Stoffel, MD
Professor, ETH Zurich Institute of Molecular Systems Biology Zurich, Switzerland |
11.45 hr |
|
Insights into insulin resistance from metabolomics analysis following bariatric surgery
Dr. Charles Burant, MD, PhD
Atkins Professor of Metabolism, University of Michigan, USA |
12.30 hr |
Lunch Break / Poster session |
Session V
Chairperson
Nancy Thornberry
Sr. VP, Metabolic Franchise Head, Merck Research Labs, USA
Dr. Gianni Gromo
Sr. VP and Global Head, Metabolic & Vascular Disease Area, Roche, Switzerland |
14.00 hr |
|
Dissecting Hypothalamic Signaling: Targeting Metabolic Disease
Dr. Jens C. Bruning, MD
Institute of Genetics, University of Cologene, Germany |
14.45 hr |
|
The dynamic interaction between food, brain and body mass index
Dr. Dana Small, PhD
Associate Professor, Department of Psychiatry Yale University School of Medicine and Associate Fellow, The John B Pierce Laboratory, USA |
15.30 hr |
Tea/Coffee Break / Poster Session |
16.00 hr |
|
ZYOG1: A Novel Oral GLP-1 agonist for treatment of Type 2 Diabetes
Dr. Mukul R. Jain, PhD
Sr. VP, Zydus Research Center, Ahmedabad, India |
16.45 hr |
|
Structure-based design of biotherapeutics with enhanced solubility and
bio-stability
Dr. Faming Zhang, PhD
CEO, Waterstone Pharmaceuticals Inc., USA. |
17.30 hr |
|
Expectations of India from global scientific community
Dr. V. M. Katoch
Secretary, Department of Health Research, Government of India &
Director-General, Indian Council of Medical Research, India |
17.50 hr |
Panel Discussion |
- Dr. Richard DiMarchi
- Nancy Thornberry
- Dr. Matthias Tschoep
- Dr. Markus Stoffel
- Dr. Charles Burant
- Dr. Jens C. Bruning
- Dr. Dana Small
- Dr. Mukul R. Jain
- Dr. Faming Zhang
- Dr. V. M. Katoch
|
19.00 hr |
Cultural Program
Venue : Hotel Courtyard Marriot
Ramdev Nagar Cross Roads, Satellite, Ahmedabad |
February 4, 2011 |
Session VI
Chairperson Dr. Charles Burant, MD, PhD
Atkins Professor of Metabolism, University of Michigan, USA
Dr. T. K. Chakraborty
Director, Central Drug Research Institute |
09.00 hr |
|
The past, present and the future of Cardiovascular translational medicine research
Dr. Gianni Gromo
Sr. VP and Global Head, Metabolic & Vascular Disease Area, Roche, Switzerland |
09.45 hr |
|
Should Safety, Drug Exposure and Clinical Efficacy of Diabetes Drugs Be Assessed in Patients or in Healthy Volunteers?
Dr. Marcus Hompesch,
President - CEO
Profil Institute for Clinical Research Inc.
California, USA
|
10.30 hr |
|
“A prospective, multi-centric, open-label, single arm study to evaluate
the safety and efficacy of 4mg of ZYH1 in hypertriglyceridemia in HIV
associated lipodystrophy”
Dr. Dhiraj Gambhire, MD
Cadila Healthcare Ltd, Mumbai, India |
11.15 hr |
Tea/Coffee Break / Poster Session |
11.45 hr |
|
Big Pharma: Leveraging for an Efficient R&D Organization
Dr. John Amatruda, MD,
Retired Merck Sr. VP & Franchise Head, Diabetes/Obesity, USA |
12.30 hr |
|
Development of Prodrug Chemistry Suitable for Application to Therapeutic Peptides
Dr. Richard DiMarchi, PhD
Gill Professor of Biochemistry, Indiana University, USA
Retired Executive VP, Lilly Research Labs., Indianapolis, USA |
13.15 hr |
Lunch Break |
14.30 hr |
|
Treatment of Metabolic Diseases with Proteins Site-Specifically Optimized for Pharmacological Use
Dr. Douglas W. Axelrod, MD, PhD
Chief Medical Officer
Senior Vice President, Development
Ambrx, Inc. |
15.15 hr |
|
Liver Selective Glucokinase Activation for Treating Type 2 Diabetes: Translation from Mouse to Man
Kasim A. Mookhtiar, Ph.D.
Chief Scientific Officer and EVP, Drug Discovery
Advinus Therapeutics Pvt Ltd, Pune, India
|
16.00 hr |
Panel Discussion |
- Dr. Richard DiMarchi
- Dr. John Amatruda
- Dr. Gianni Gromo
- Dr. Marcus Hompesch
- Dr. Douglas W. Axelrod
- Dr. Kasim A. Mookhtiar
|
16.30 hr |
|
Best Posters Award
- Three selected posters will be announced for prize presentation.
- Time of 10 mins each will be provided to the 3 best posters for podium presentation.
|
17.00 hr |
Wrap-up session |
|
|